Grünenthal Meds

Grünenthal Meds was established in August 2023, as part of a Joint Venture Collaboration between Grünenthal and Kyowa Kirin. Headquartered in the UK, we are responsible for managing a portfolio of 13 medicines across six key therapeutic areas, including cancer pain, constipation, and bone health. Through a network of affiliates and key partners, we are bringing these important products to patients in need around the globe.